SYMQY (SymBio Pharmaceuticals) Payments of Debt: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SYMQY SymBio Pharmaceuticals Ltd SYMQY
36 GF Score
Price $0.56
GF Value $0.48
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Payments of Debt?

SymBio Pharmaceuticals SYMQY -12.42% 36 Payments of Debt is $0.00 Mil as of Dec. 2025. GuruFocus rates SYMQY with a GF Score™ of 36/100 and a GF Value™ of $0.48. The stock has 6 warning signs investors should review.

SymBio Pharmaceuticals's Payments of Debt for the three months ended in Dec. 2025 was $0.00 Mil.

SymBio Pharmaceuticals's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

SymBio Pharmaceuticals Payments of Debt Related Terms

SymBio Pharmaceuticals Payments of Debt Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Payments of Debt Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -3.54

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SYMQY
36GF Score
SymBio Pharmaceuticals Ltd SYMQY
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
SymBio Pharmaceuticals (SYMQY) has a Payments of Debt of $0.00 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Payments of Debt too high?
SymBio Pharmaceuticals' current Payments of Debt is $0.00 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Payments of Debt compare to ZTS?
SymBio Pharmaceuticals' Payments of Debt of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Payments of Debt of $0.00 Mil. The stock's GF Value™ is $0.48, compared to a current price of $0.56 — trading 16.2% above its estimated fair value. The current Payments of Debt is $0.00 Mil. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Payments of Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of $0.56 is trading 16.2% above its estimated GF Value™ of $0.48.

Key valuation signals for SYMQY:

  • Payments of Debt: $0.00 Mil
  • GF Value™: $0.48 vs. price of $0.56 (16.2% above fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Other Exchanges 4582:Japan
Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for SYMQY

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.48
GF Value